Similarly, in a small study in 28 patients with polycystic ovary syndrome (PCOS), treatment with atorvastatin 20 mg compared to placebo over 6 months led to a decrease in insulin sensitivity despite a decrease in the inflammatory marker C-reactive protein (CRP)27. This evidence concerns the gene CRP and polycystic ovary syndrome.